Brief: Cipla Announces Launch Of Generic Saxenda For Weight Management Therapy
27/02/2026 17:29
Feb 27 (Reuters) - Cipla Ltd CIPL.NS: CIPLA STRENGTHENS US PORTFOLIO WITH THE LAUNCH OF GENERIC SAXENDA® (LIRAGLUTIDE INJECTION) FOR WEIGHT MANAGEMENT THERAPY CIPLA: TO LAUNCH GENERIC SAXENDA ON AN IMMEDIATE BASIS Source text: ID:nPn2VJ63Sa Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate